Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
YARDLEY, Pa., March 02, 2017 -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a regenerative technologies company committed to restoring tissue and rebuilding lives, today announced that David Johnson, Chief Executive Officer, and Brian Posner, Chief Financial Officer, will attend the Cowen and Company 37th Annual Health Care Conference at the Boston Marriott Copley Place in Boston, Massachusetts.
Management will present on Wednesday, March 8th at 9:20 a.m. Eastern Time (ET). A live webcast of the conference presentation will be available on the investor relations section of the Company’s website at http://ir.alliqua.com. An archived copy of the webcast will be available for replay following the event.
About Alliqua BioMedical, Inc.
Alliqua is a regenerative technologies company committed to restoring tissue and rebuilding lives. Through its sales and distribution network, together with its proprietary products, Alliqua offers solutions that allow clinicians to utilize the latest advances in regenerative technologies to bring improved patient outcomes to their practices.
Alliqua currently markets the human biologic regenerative technologies, Biovance® and Interfyl®. The Company also markets its Mist Therapy System®, which uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process. In addition to these technologies, Alliqua markets its line of dressings for wound care under the SilverSeal® and Hydress® brands, as well as its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its hydrogel technology. The Company has locations in Yardley, Pennsylvania, Langhorne, Pennsylvania and Eden Prairie, Minnesota.
For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.
Investor Relations: Westwicke Partners on behalf of Alliqua Biomedical, Inc. Mike Piccinino, CFA +1-443-213-0500 [email protected]
